Medtronic Q1 2027 Earnings Analysis

More earnings analysis: https://betafinch.comGroups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)──────────WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one.JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day.ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: With that out of the way, let's get into the numbers, because they were strong.ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter.JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating.ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight.JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone.ALEX: Nine points in one quarter is wild for medtech.JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before.ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts.JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially.ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S.JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it.ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system.JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028.ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris.JORDAN: On guidance, they raThis episode includes AI-generated content.